Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBIT (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBIT readings, the most recent being -$5.6 million for Q4 2025.

  • On a quarterly basis, EBIT fell 287.34% to -$5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$40.4 million, a 96.78% decrease, with the full-year FY2025 number at -$40.4 million, down 96.77% from a year prior.
  • EBIT hit -$5.6 million in Q4 2025 for Cytek Biosciences, up from -$9.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $3.8 million in Q2 2021 to a low of -$15.0 million in Q1 2025.
  • Median EBIT over the past 5 years was -$3.3 million (2022), compared with a mean of -$4.1 million.
  • Biggest five-year swings in EBIT: tumbled 924.35% in 2023 and later skyrocketed 2279.56% in 2024.
  • Cytek Biosciences' EBIT stood at $1.3 million in 2021, then tumbled by 93.62% to $84000.0 in 2022, then crashed by 263.1% to -$137000.0 in 2023, then skyrocketed by 2279.56% to $3.0 million in 2024, then plummeted by 287.34% to -$5.6 million in 2025.
  • The last three reported values for EBIT were -$5.6 million (Q4 2025), -$9.2 million (Q3 2025), and -$10.6 million (Q2 2025) per Business Quant data.